EpiPen patent expiry opens new era for innovation
Pharmaceutical Technology
AUGUST 8, 2025
Mylan acquired the rights to the injector pen for treating anaphylactic reactions following the $6.7bn acquisition of Merck KGaA’s generics business, Merck Generics, in 2007. Go deeper with GlobalData Reports NPVM: Epipen Data Insights The gold standard of business intelligence.
Let's personalize your content